Background–Polycystic ovary syndrome (PCOS) is the commonest endocrine–disorder in the women of the reproductive age. Pathogenesis has not been fully solved. PCOS is related with the insulin resistance (IR), the menstrual irregularities, cardiovascular disease (CVD), endometrial cancer, obesity, hirsutism, and infertility. Using myo–inositol (MI) and D–chiro–inositol (DCI) for treatment of menstrual irregularities in PCOS women has been disputable with incompatible data being published.

Aim & Objective– To compare the combined effect of D–Chiroinositol (DCI) and myo–inositol (MI), in PCOS women to check menstrual irregularities

Material and Method–This  randomized clinical trial was performed on 450 north Indian women attending Gynae OPD in Hind Institute of Medical Sciences diagnosed with PCOS  according to Rotterdams criteria and treated with MI and DCI (Myo inositol and D Chiroinositol) combination or Myoinositol plus folic acid . Patients aged 15 to 40 years were selected randomly and a questionnaire covering the personaldetails, status of health, medications, anthropometrics and physical activity was completed beforehand and divided them into 2 groups: 225 were treated with Myo inositol and D Chiroinositol, 225 with Myo inositol plus placebo (folic acid only). We analyzed both the groups pre–treatment & post–treatment.

Result–The prevalence of obesity in the present population was 29.3%. The menstrual dysfunction was prevalent among the obese women with the polycystic ovary syndrome; the non–obese patients were also having the significant incidence of Insulin Resistance menstrual dysfunction. After three months course of treatment with MI and DCI the significant decrease in the fasting glucose, Low–Density Lipoprotein (LDL), HOMA–IR, Triglycerides (TG), Body mass index (BMI), Glycated Hemoglobin (HbA1c), weight and levels were noted.

Conclusion–In present study, we concluded that the combination of MI & DCI can improve the menstrual dysfunction and metabolic profile in PCOS women.